Clinical trial NCT03185065: Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Official title: Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Fatigue in Multiple Sclerosis
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: Patient-Centered Outcomes Research Institute
First posted: 2017-06-14
Enrollment: 141
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind, multicenter trial of 3 commonly used medications for treatment of Multiple Sclerosis related fatigue versus placebo in fatigued subjects with MS.
Primary purpose: TREATMENT

Brief summary: Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.

Detailed description: This is a randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.

Using a balanced Latin-square crossover design, subjects will be allocated, in a double-blind, randomized fashion, to one of the four treatment sequences (Figure 1): 1) amantadine, placebo, modafinil, methylphenidate; 2) placebo, methylphenidate, amantadine, modafinil; 3) modafinil, amantadine, methylphenidate, placebo; and 4) methylphenidate, modafinil, placebo and amantadine. Each medication will be titrated over four weeks to the participants' highest tolerated dose or the pre-defined highest dose. The dosing and titration schedule of the study medications are depicted in Figure 2. Each treatment period will be 6 weeks and there will be a 2-week washout period between each treatment period. At the beginning of the trial, a biostatistician at University of California, San Francisco (UCSF) will prepare a concealed allocation schedule, randomly assigning the four sequences, in blocks of 4, to a consecutive series of numbers and at the time of enrollment, each participant will be assigned the next consecutive number (and hence the sequence of study medications).

The primary endpoint of the study will be fatigue severity as measured by the MFIS score, between 26th and 35th day of each treatment period (while the patient is taking the maximal tolerated or target dose). The MFIS is a validated patient-reported outcome. The questionnaire will be administered remotely (through internet, phone or mailed forms) and the participants can answer the questions in few minutes while at home or at their work place. The questionnaire has been validated in English and Spanish.

Eligibility criteria: Inclusion criteria:

* Age 18 years and older.
* Females of childbearing age must have a negative urine pregnancy test at baseline and use an effective method of contraception during the study.
* Diagnosis of MS (according to the 2010 McDonald criteria).
* Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.
* Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score more than 33.
* At least a two-week washout for any fatigue-related drug, including study medications.

Exclusion criteria:

* Neurodegenerative disorders other than relapsing or progressive MS.
* Breastfeeding or pregnant.
* History of coronary artery disease or congestive heart failure.
* Uncontrolled hypertension at screening (history of high blood pressure and screening systolic blood pressure \>160 or diastolic blood pressure\>100).
* Glomerular Filtration Rate (GFR) (glomerular filtration rate) \< 50.
* Abnormal liver function at screening (AST or Alanine Aminotransferase (ALT) more than twice the upper limit of normal).
* Terminal medical conditions.
* Currently treated for active malignancy.
* Planned surgery or move within 8 months of screening.
* Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).
* A history of intolerance or allergic or anaphylactic reaction to amantadine, modafinil, methylphenidate or any component of the preparation.
* Clinically unstable medical or psychiatric disorders that require acute treatment as determined by the PI.
* Concurrent use of monoamine oxidase inhibitors-B.
* Hypersensitivity/idiosyncrasy to sympathomimetic amines
* Inability to communicate or answer the questionnaires in English or Spanish.
* Severe untreated anemia (blood hemoglobin \<9gr/dl)
* History of untreated hypothyroidism
* History of untreated sleep apnea
* History of long QT syndrome, atrial fibrillation or tachyarrhythmias (other than sinus tachycardia)
* History of ischemic or hemorrhagic stroke
* History of glaucoma
* History of Tourette syndrome

Primary outcomes:
measure: Modified Fatigue Impact Scale (MFIS) Score
timeFrame: Week 5 of each treatment period
Secondary outcomes:
measure: Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score
timeFrame: Week 5 of each treatment period
measure: Epworth Sleepiness Scale (ESS) Score
timeFrame: Week 5 of each treatment period
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Bardia Nourbakhsh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021 Jan;20(1):38-48. doi: 10.1016/S1474-4422(20)30354-9. Epub 2020 Nov 23.
citation: Nourbakhsh B, Revirajan N, Waubant E. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemp Clin Trials. 2018 Jan;64:67-76. doi: 10.1016/j.cct.2017.11.005. Epub 2017 Nov 4.